Compare stocks

Medios AG, headquartered in Berlin, Germany, specializes in the supply and manufacturing of specialty pharmaceutical products, focusing on treatments for chronic and rare diseases. The company operates through two primary segments: Pharmaceutical Supply, offering a portfolio of approximately 1,000 specialty pharma drugs across therapeutic areas such as oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia; and Patient-Specific Therapies, producing individualized medications, including cytostatic infusions, antibody therapies, virostatic and antibiotic medications, and parenteral nutrition solutions, with around 400,000 preparations completed in fiscal year 2023. Founded in 2016, Medios AG has expanded its geographic footprint to include operations in Germany, the Netherlands, Belgium, and Spain. The company's strategic positioning emphasizes individualized medicine, collaborating with pharmacies, specialist practices, and pharmaceutical companies to make innovative therapies widely accessible.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.